MARIETTA, Ga., Sept. 30, 2014 /PRNewswire/ -- MiMedx Group, Inc.
(NASDAQ: MDXG), the leading regenerative medicine company utilizing
human amniotic tissue and patent-protected processes to develop and
market advanced products and therapies for the Wound Care,
Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and
Dental sectors of healthcare, announced today that Dr.
Tom Koob, Ph.D., Chief Scientific
Officer, will present at the Stem Cell Meeting on the Mesa. Dr.
Koob will present on Tuesday, October 7,
2014, at 5:00PM Pacific Daylight
Time.
The Stem Cell Meeting on the Mesa is a three-day conference
bringing together key opinion leaders, senior executives and top
decision-makers in the regenerative medicine and advanced therapies
industry with the scientific community to advance cutting-edge
research into cures. The meeting features a nationally recognized
Scientific Symposium, attended by leading researchers and clinical
experts from around the globe, in conjunction with the industry's
premier annual Partnering Forum, the first and only event of its
kind dedicated to facilitating connections in this sector. The
three-day meeting held in La Jolla,
California, begins on Tuesday,
October 7, 2014 and concludes on Thursday, October 9, 2014.
Dr. Koob has published over 125 biomedical and biological
articles and 12 book chapters, and he is listed as an inventor on
over 40 issued and pending patents. MiMedx is actively involved in
state-of-the-art scientific research directed towards a complete
understanding of the mechanisms of action underlying the clinical
effectiveness of the Company's dehydrated human amnion chorion
membrane ("dHACM") allografts. Six scientific studies have
been conducted on the effects of dHACM on human cells involved in
wound healing and tissue regeneration. In all six of the studies
completed to date, peer-reviewed articles have been published in
the scientific literature. Dr. Koob has been instrumental in all of
these studies and publications.
About MiMedx
MiMedx® is an integrated developer, processor and marketer of
patent protected regenerative biomaterial products and bioimplants
processed from human amniotic membrane. "Innovations in
Regenerative Biomaterials" is the framework behind our
mission to give physicians products and tissues to help the body
heal itself. Our biomaterial platform technologies include
AmnioFix® and EpiFix®, our tissue technologies processed from human
amniotic membrane that is derived from donated placentas. Through
our donor program, mothers delivering full-term Caesarean section
births can elect in advance of delivery to donate the placenta in
lieu of having it discarded as medical waste. We process the human
amniotic membrane utilizing our proprietary PURION® Process, to
produce a safe and effective implant. MiMedx® is the leading
supplier of amniotic tissue, having supplied over 275,000
allografts to date for application in the Wound Care, Surgical,
Sports Medicine, Ophthalmic and Dental sectors of healthcare.
SOURCE MiMedx Group, Inc.